BMS/Pfizer set for European Eliquis launch after VTE prevention approval

Bristol-Myers Squibb and Pfizer are set for European launches of their oral direct Factor Xa inhibitor, Eliquis (apixaban), after receiving approval from the European Commission for its use in the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

Bristol-Myers Squibb and Pfizer are set for European launches of their oral direct Factor Xa inhibitor, Eliquis (apixaban), after receiving approval from the European Commission for its use in the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

"We would anticipate that Eliquis will be available in some countries within a week of the approval [on 20 May]....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapeutic Category

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.